ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ENDRA Life Sciences Inc. (NDRA) on April 27, 2020, covering events occurring on April 21, 2020, and April 24, 2020. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Ann Arbor, Michigan.
Key Financial Metrics and Debt
- Debt Financing: The Company secured a loan under the Small Business Administration (SBA) Paycheck Protection Program (PPP).
- Principal Amount: $308,600.00.
- Interest Rate: 1.00% per annum.
- Maturity Date: April 22, 2022 (2-year term).
- Repayment Terms: No payments due for the first seven months (Deferment Period); interest accrues during this period. Monthly principal and interest payments follow unless forgiven.
- Collateral: None provided.
- Revenue and Profit: The filing text does not provide a clear value for revenue, profit, cash flow, or margins.
Material Changes and Listing Status
On April 24, 2020, the Company received notification from The Nasdaq Stock Market LLC regarding a failure to meet the minimum bid price requirement for continued listing.
- Deficiency: The closing bid price for the Company's common stock was below $1.00 for 30 consecutive trading days.
- Compliance Period: The Company has 180 calendar days from July 1, 2020, until December 28, 2020, to regain compliance.
- Compliance Criteria: The bid price must close at or above $1.00 per share for a minimum of 10 consecutive business days.
- Consequences: Failure to comply by the deadline may result in delisting, though the Company may be eligible for an additional 180-day period if it meets other listing standards (e.g., market value of publicly held shares) and potentially effects a reverse stock split.
Guidance, Risks, and Contingencies
- Loan Forgiveness Risk: There is no assurance that the PPP Loan will be forgiven in whole or in part. Forgiveness depends on using funds for payroll (at least 75%), rent, and utilities, and maintaining employee headcount and salary levels.
- Delisting Risk: If the Company fails to cure the bid price deficiency by December 28, 2020, or fails to qualify for an extension, its securities may be delisted from Nasdaq.
- Default Provisions: The Note includes customary events of default, including failure to make payments, bankruptcy, or material adverse changes in financial condition, which could trigger immediate repayment of all amounts owing.
Investor Verification Checklist
- Verify the Company's ability to maintain the $1.00 minimum bid price for 10 consecutive days before December 28, 2020.
- Confirm the allocation of the $308,600 PPP loan proceeds to ensure eligibility for forgiveness (specifically the 75% payroll cost threshold).
- Monitor future filings (Form 10-Q) for the full text of the Note and updated financial position.
- Assess the Company's liquidity position given the upcoming repayment obligations if loan forgiveness is not granted.